Last reviewed 2026-05-23 · How we verify

Tibamax (TYBAMATE)

Phase 2 active Small molecule ✓ Verified May 2026

Tibamax (generic name: TYBAMATE) is a drug. It is currently in Phase 2 development.

Tibamax is thought to work by modulating neurotransmitter activity in the brain.

Tibamax is a small molecule with the synonyms NSC-172126, SOLACEN, TIBAMATO, TYBAMATE.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TYBAMATE
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a city with many different streets and intersections. Tibamax is like a traffic light that helps regulate the flow of information between different parts of the city, allowing the right signals to get through and the wrong ones to be blocked. This can help to calm down overactive areas of the brain and improve communication between different regions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tibamax CI brief — competitive landscape report
Tibamax updates RSS · CI watch RSS

Frequently asked questions about Tibamax

What is Tibamax?

Tibamax (TYBAMATE) is a Small molecule drug.

How does Tibamax work?

Tibamax is thought to work by modulating neurotransmitter activity in the brain.

What is the generic name of Tibamax?

TYBAMATE is the generic (nonproprietary) name of Tibamax.

What development phase is Tibamax in?

Tibamax is in Phase 2.

Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing